Saatci M.Deliormanlı A.M.Atmaca H.2024-07-222024-07-22202202728842http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12395Osteosarcoma is one of the most common types of bone cancer, which generally starts in the long bones. In this study, superparamagnetic maghemite-containing (2, 5, 10, 20 wt%) bioactive glass powders were prepared for the treatment of osteosarcoma. For this purpose, maghemite nanoparticles were synthesized using the co-precipitation technique, and maghemite-containing bioactive glass-ceramic composites were fabricated through the sol-gel process. The structural, morphological, thermal, and magnetic properties and the in vitro bioactivity of the prepared bioactive glasses were investigated. In vitro cytotoxicity was examined using SaOS-2 and MC3T3-E1 cells. The fluorouracil (5-FU) release behavior of the studied bioactive glass powders was also monitored in phosphate-buffered saline as a function of time. Results revealed that synthesized maghemite nanoparticles as well as the maghemite-containing bioactive glass-ceramic composites have superparamagnetic properties. They have high bioactivity, with up to 5 wt% maghemite content. Prepared bioactive glass composites have no cytotoxicity against osteosarcoma and pre-osteoblast cells at low concentrations. Drug-loaded bioactive glass powder showed sustained release behavior. Overall results indicated that prepared glass composites have a high potential to be used in magnetic hyperthermia and anticancer drug release applications for the treatment of bone cancer. © 2022 Elsevier Ltd and Techna Group S.r.l.EnglishBioactivityControlled drug deliveryDiseasesGlass ceramicsHematiteHyperthermia therapyNanoparticlesPowdersPrecipitation (chemical)Sol-gel processSol-gelsSuperparamagnetismSynthesis (chemical)Targeted drug deliveryBioactive glass ceramicsBone cancerGlass ceramic compositesGlass PowderIn-vitroMaghemite nanoparticleMaghemitesOsteosarcomasSuperparamagneticsSynthesisedBioactive glassArticle10.1016/j.ceramint.2022.08.017